Nontuberculous Mycobacteria in Patients with Cystic Fibrosis

Abstract

As a result of their underlying lung disease, patients with cystic fibrosis (CF) have a higher risk of developing nontuberculous mycobacteria (NTM) infections compared with the general population. Although NTM may be present intermittently in low amounts in the airways of CF patients without an apparent clinical effect, progressive respiratory decline due to NTM disease may also occur. Identifying this latter group of patients can be challenging for clinicians because the usual symptoms exhibited by infected individuals without CF may be difficult to distinguish from the baseline respiratory dysfunction of a patient with CF. The distinction, however, is of utmost importance because those patients with clinical worsening may benefit considerably from antimycobacterial treatment. For CF patients under evaluation for lung transplantation, NTM can play a critical role in determining overall outcomes, and treatment in the pre- and post-transplant period may be vital to success. A general approach to NTM in CF thus involves surveillance to detect NTM, careful monitoring for associated clinical decline, and consideration of treatment given for those with an otherwise unexplained deterioration. In this review, the epidemiology and clinical course of NTM in CF is described with an algorithm for management proposed.

Keywords

cystic fibrosis - nontuberculous mycobacteria - mycobacterium infections - Mycobacterium avium complex - Mycobacterium abscessus

• References

• 1 Hamosh A, FitzSimmons SC, Macek Jr M, Knowles MR, Rosenstein BJ, Cutting GR. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr 1998; 132 (2) 255-259
• 2 Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151 (4) 1075-1082
• 3 Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999; 160 (1) 186-191
• 4 Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995; 20 (2) 63-70
• 5 Mearns MB, Hunt GH, Rushworth R. Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-71. Arch Dis Child 1972; 47 (256) 902-907
• 6 Rosenfeld M, Gibson RL, McNamara S , et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001; 32 (5) 356-366
• 7 Cystic Fibrosis Foundation Patient Registry. Annual Data Report 2009;
• 8 Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009; 136 (6) 1554-1560
• 9 Millar FA, Simmonds NJ, Hodson ME. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. J Cyst Fibros 2009; 8 (6) 386-391
• 10 Li Z, Kosorok MR, Farrell PM , et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293 (5) 581-588
• 11 Reid DW, Blizzard CL, Shugg DM, Flowers C, Cash C, Greville HM. Changes in cystic fibrosis mortality in Australia, 1979-2005. Med J Aust 2011; 195 (7) 392-395
• 12 George PM, Banya W, Pareek N , et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ 2011; 342: d1008
• 13 Boxerbaum B. Isolation of rapidly growing mycobacteria in patients with cystic fibrosis. J Pediatr 1980; 96 (4) 689-691
• 14 Hjelte L, Petrini B, Källenius G, Strandvik B. Prospective study of mycobacterial infections in patients with cystic fibrosis. Thorax 1990; 45 (5) 397-400
• 15 Kilby JM, Gilligan PH, Yankaskas JR, Highsmith Jr WE, Edwards LJ, Knowles MR. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 1992; 102 (1) 70-75
• 16 Aitken ML, Burke W, McDonald G, Wallis C, Ramsey B, Nolan C. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest 1993; 103 (4) 1096-1099
• 17 Cullen AR, Cannon CL, Mark EJ, Colin AA. Mycobacterium abscessus infection in cystic fibrosis: colonization or infection?. Am J RespirCrit Care Med 2000; 161 (2 Pt 1) 641-645
• 18 Rodman DM, Polis JM, Heltshe SL , et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005; 171 (6) 621-626
• 19 Olivier KN, Weber DJ, Wallace Jr RJ , et al; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167 (6) 828-834
• 20 Forslöw U, Geborek A, Hjelte L, Petrini B, Heurlin N. Early chemotherapy for non-tuberculous mycobacterial infections in patients with cystic fibrosis. Acta Paediatr 2003; 92 (8) 910-915
• 21 Leitritz L, Griese M, Roggenkamp A, Geiger AM, Fingerle V, Heesemann J. Prospective study on nontuberculous mycobacteria in patients with and without cystic fibrosis. Med Microbiol Immunol (Berl) 2004; 193 (4) 209-217
• 22 Esther Jr CR, Henry MM, Molina PL, Leigh MW. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005; 40 (1) 39-44
• 23 Girón RM, Máiz L, Barrio I, Martínez MT, Salcedo A, Prados C. Nontuberculous mycobacterial infection in patients with cystic fibrosis: a multicenter prevalence study [in Spanish]. Arch Bronconeumol 2008; 44 (12) 679-684
• 24 Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C , et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis 2003; 9 (12) 1587-1591
• 25 Esther Jr CR, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9 (2) 117-123
• 26 Roux AL, Catherinot E, Ripoll F , et al; Jean-Louis Herrmann for the OMA Group. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. J Clin Microbiol 2009; 47 (12) 4124-4128
• 27 Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I , et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol 2005; 43 (7) 3467-3470
• 28 Cystic Fibrosis Foundation Patient Registry. Annual Data Report 2010. www.cff.org/UploadedFiles/LivingWithCF/CareCenterNetwork/PatientRegistry/2010-Patient-Registry-Report.pdf
• 29 Torrens JK, Dawkins P, Conway SP, Moya E. Non-tuberculous mycobacteria in cystic fibrosis. Thorax 1998; 53 (3) 182-185
• 30 Smith MJ, Efthimiou J, Hodson ME, Batten JC. Mycobacterial isolations in young adults with cystic fibrosis. Thorax 1984; 39 (5) 369-375
• 31 Hjelt K, Højlyng N, Howitz P , et al. The role of Mycobacteria Other Than Tuberculosis (MOTT) in patients with cystic fibrosis. Scand J Infect Dis 1994; 26 (5) 569-576
• 32 Fauroux B, Delaisi B, Clément A , et al. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J 1997; 16 (4) 354-358
• 33 Nick JA. Nontuberculous mycobacteria in cystic fibrosis. Semin Respir Crit Care Med 2003; 24 (6) 693-702
• 34 Satyanarayana G, Heysell SK, Scully KW, Houpt ER. Mycobacterial infections in a large Virginia hospital, 2001–2009. BMC Infect Dis 2011; 11: 113
• 35 Levy I, Grisaru-Soen G, Lerner-Geva L , et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis 2008; 14 (3) 378-384
• 36 Falkinham III JO. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol 2009; 107 (2) 356-367
• 37 Radhakrishnan DK, Yau Y, Corey M , et al. Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. Pediatr Pulmonol 2009; 44 (11) 1100-1106
• 38 Paugam A, Baixench MT, Demazes-Dufeu N , et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol 2010; 48 (Suppl. 01) S32-S36
• 39 Mussaffi H, Rivlin J, Shalit I, Ephros M, Blau H. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005; 25 (2) 324-328
• 40 Olivier KN, Weber DJ, Lee JH , et al; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria, II: Nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 167 (6) 835-840
• 41 Renna M, Schaffner C, Brown K , et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011; 121 (9) 3554-3563
• 42 Griffith DE, Aksamit T, Brown-Elliott BA , et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175 (4) 367-416 (dosage error corrected in Am J Respir Crit Care Med 2007;175(7):744–745)
• 43 Bange FC, Brown BA, Smaczny C, Wallace Jr RJ, Böttger EC. Lack of transmission of mycobacterium abscessus among patients with cystic fibrosis attending a single clinic. Clin Infect Dis 2001; 32 (11) 1648-1650
• 44 Saiman L, Siegel J. Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003; 31 (3, Suppl) S1-S62
• 45 Aitken ML, Limaye A, Pottinger P , et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012; 185 (2) 231-232
• 46 Whittier S, Hopfer RL, Knowles MR, Gilligan PH. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 1993; 31 (4) 861-864
• 47 Whittier S, Olivier K, Gilligan P, Knowles M, Della-Latta P. The Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Proficiency testing of clinical microbiology laboratories using modified decontamination procedures for detection of nontuberculous mycobacteria in sputum samples from cystic fibrosis patients. J Clin Microbiol 1997; 35 (10) 2706-2708
• 48 Bange FC, Kirschner P, Böttger EC. Recovery of mycobacteria from patients with cystic fibrosis. J Clin Microbiol 1999; 37 (11) 3761-3763
• 49 Ferroni A, Vu-Thien H, Lanotte P , et al. Value of the chlorhexidine decontamination method for recovery of nontuberculous mycobacteria from sputum samples of patients with cystic fibrosis. J Clin Microbiol 2006; 44 (6) 2237-2239
• 50 Esther Jr CR, Hoberman S, Fine J , et al. Detection of rapidly growing mycobacteria in routine cultures of samples from patients with cystic fibrosis. J Clin Microbiol 2011; 49 (4) 1421-1425
• 51 Oliver A, Maiz L, Cantón R, Escobar H, Baquero F, Gómez-Mampaso E. Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis 2001; 32 (9) 1298-1303
• 52 Kubica GP, Dye WE, Cohn ML, Middlebrook G. Sputum digestion and decontamination with N-acetyl-L-cysteine-sodium hydroxide for culture of mycobacteria. Am Rev Respir Dis 1963; 87: 775-779
• 53 Martin ME, Horton CL, Sheffner AL, Solomon JD. Direct comparison of the N-acetyl-l-cysteine-sodium hydroxide and the trisodium phosphate digestion methods for the culture of mycobacteria. Appl Microbiol 1968; 16 (3) 506-508
• 54 Whittaker LA, Teneback C. Atypical mycobacterial and fungal infections in cystic fibrosis. Semin Respir Crit Care Med 2009; 30 (5) 539-546
• 55 Cystic Fibrosis Foundation Patient Registry. Annual Data Report 1997. Bethesda, MD: Cystic Fibrosis Foundation; 1997
• 56 Bange FC, Böttger EC. Improved decontamination method for recovering mycobacteria from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2002; 21 (7) 546-548
• 57 Portaels F. Epidemiology of mycobacterial diseases. Clin Dermatol 1995; 13 (3) 207-222
• 58 Thoen CO, Himes EM, Jarnagin JL, Harrington Jr R. Comparison of four culture media for isolation of Mycobacterium avium complex from porcine tissues. J Clin Microbiol 1979; 9 (2) 194-196
• 59 Peterson EM, Lu R, Floyd C, Nakasone A, Friedly G, de la Maza LM. Direct identification of Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium intracellulare from amplified primary cultures in BACTEC media using DNA probes. J Clin Microbiol 1989; 27 (7) 1543-1547
• 60 Idigoras P, Pérez-Trallero E, Alcorta M, Gutiérrez C, Muñoz-Baroja I. Rapid detection of tuberculous and non-tuberculous mycobacteria by microscopic observation of growth on Middlebrook 7H11 agar. Eur J Clin Microbiol Infect Dis 1995; 14 (1) 6-10
• 61 Wilson ML, Stone BL, Hildred MV, Reves RR. Comparison of recovery rates for mycobacteria from BACTEC 12B vials, Middlebrook 7H11-selective 7H11 biplates, and Lowenstein Jensen slants in a public health mycobacteriology laboratory. J Clin Microbiol 1995; 33 (9) 2516-2518
• 62 Ngan GJ, Ng LM, Jureen R, Lin RT, Teo JW. Development of multiplex PCR assays based on the 16S-23S rRNA internal transcribed spacer for the detection of clinically relevant nontuberculous mycobacteria. Lett Appl Microbiol 2011; 52 (5) 546-554
• 63 Leung KL, Yip CW, Cheung WF, Lo AC, Ko WM, Kam KM. Development of a simple and low-cost real-time PCR method for the identification of commonly encountered mycobacteria in a high throughput laboratory. J Appl Microbiol 2009; 107 (5) 1433-1439
• 64 Devine M, Moore JE, Xu J , et al. Detection of mycobacterial DNA from sputum of patients with cystic fibrosis. Ir J Med Sci 2004; 173 (2) 96-98
• 65 Mulherin D, Coffey MJ, Halloran DO, Keogan MT, FitzGerald MX. Skin reactivity to atypical mycobacteria in cystic fibrosis. Respir Med 1990; 84 (4) 273-276
• 66 Cocito CG. Properties of the mycobacterial antigen complex A60 and its applications to the diagnosis and prognosis of tuberculosis. Chest 1991; 100 (6) 1687-1693
• 67 Caminero JA, Rodriguez de Castro F, Carrillo T, Diaz F, Rodriguez Bermejo JC, Cabrera P. Diagnosis of pleural tuberculosis by detection of specific IgG anti-antigen 60 in serum and pleural fluid. Respiration 1993; 60 (1) 58-62
• 68 Ferroni A, Sermet-Gaudelus I, Le Bourgeois M , et al. Measurement of immunoglobulin G against Mycobacterial antigen A60 in patients with cystic fibrosis and lung infection due to Mycobacterium abscessus. Clin Infect Dis 2005; 40 (1) 58-66
• 69 Boxerbaum B. Isolation of rapidly growing mycobacteria in patients with cystic fibrosis. J Pediatr 1980; 96 (4) 689-691
• 70 Tomashefski Jr JF, Stern RC, Demko CA, Doershuk CF. Nontuberculous mycobacteria in cystic fibrosis: an autopsy study. Am J Respir Crit Care Med 1996; 154 (2 Pt 1) 523-528
• 71 Ebert DL, Olivier KN. Nontuberculous mycobacteria in the setting of cystic fibrosis. Clin Chest Med 2002; 23 (3) 655-663
• 72 Hodson ME. Bacterial infection in cystic fibrosis (CF): special reference to mycobacteria and Burkholderia cepacia. Pediatr Pulmonol Suppl 1995; 11: 66-67
• 73 Efthimiou J, Smith MJ, Hodson ME, Batten JC. Fatal pulmonary infection with Mycobacterium fortuitum in cystic fibrosis. Br J Dis Chest 1984; 78 (3) 299-302
• 74 Catherinot E, Roux AL, Macheras E , et al. Acute respiratory failure involving an R variant of Mycobacterium abscessus. J Clin Microbiol 2009; 47 (1) 271-274
• 75 Razvi S, Saiman L. Nontuberculous mycobacteria in cystic fibrosis. Pediatr Infect Dis J 2007; 26 (3) 263-264
• 76 Griffith DE. Risk-benefit assessment of therapies for Mycobacterium avium complex infections. Drug Saf 1999; 21 (2) 137-152
• 77 Quittell LM. Management of non-tuberculous mycobacteria in patients with cystic fibrosis. Paediatr Respir Rev 2004; 5 (Suppl A): S217-S219
• 78 Hayes Jr D. Mycobacterium abscessus and other nontuberculous mycobacteria: evolving respiratory pathogens in cystic fibrosis: a case report and review. South Med J 2005; 98 (6) 657-661
• 79 Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168 (8) 918-951
• 80 Griffith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2012; 25 (2) 218-227
• 81 Huang YC, Liu MF, Shen GH , et al. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing. J Microbiol Immunol Infect 2010; 43 (5) 401-406
• 82 Döring G, Conway SP, Heijerman HG , et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16 (4) 749-767
• 83 Kearns GL, Trang JM. Introduction to pharmacokinetics: aminoglycosides in cystic fibrosis as a prototype. J Pediatr 1986; 108 (5 Pt 2) 847-853
• 84 de Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance. Clin Pharmacokinet 1987; 13 (4) 228-253
• 85 Rey E, Tréluyer JM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35 (4) 313-329
• 86 Reed MD, Spino M. Clinical pharmacokinetics: concepts to practice. In: Orenstein DM, Stern RC, , eds. Treatment of the Hospitalized Cystic Fibrosis Patient. New York, NY: Marcel Dekker; 1998: 301-355
• 87 Gilljam M, Berning SE, Peloquin CA, Strandvik B, Larsson LO. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J 1999; 14 (2) 347-351
• 88 Alcaide F, Calatayud L, Santín M, Martín R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 2004; 48 (12) 4562-4565
• 89 Cavusoglu C, Soyler I, Akinci P. Activities of Linezolid against nontuberculous mycobacteria. New Microbiol 2007; 30 (4) 411-414
• 90 Brown-Elliott BA, Crist CJ, Mann LB, Wilson RW, Wallace Jr RJ. In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria. Antimicrob Agents Chemother 2003; 47 (5) 1736-1738
• 91 Cremades R, Santos A, Rodríguez JC, Garcia-Pachón E, Ruiz M, Royo G. Mycobacterium abscessus from respiratory isolates: activities of drug combinations. J Infect Chemother 2009; 15 (1) 46-48
• 92 Cremades R, Santos A, Rodríguez JC, Garcia-Pachon E, Ruiz M, Royo G. In vitro bactericidal activity of antibiotic combinations against clinical isolates of Mycobacterium chelonae. J Chemother 2008; 20 (1) 43-47
• 93 Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012; 67 (2) 290-298
• 94 Rastogi N, Goh KS, Bryskier A, Devallois A. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob Agents Chemother 1996; 40 (11) 2483-2487
• 95 Levin RH, Bolinger AM. Treatment of nontuberculous mycobacterial infections in pediatric patients. Clin Pharm 1988; 7 (7) 545-551
• 96 Shen GH, Wu BD, Hu ST, Lin CF, Wu KM, Chen JH. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010; 35 (4) 400-404
• 97 van Ingen J, van der Laan T, Dekhuijzen R, Boeree M, van Soolingen D. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents 2010; 35 (2) 169-173
• 98 da Silva Telles MA, Chimara E, Ferrazoli L, Riley LW. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates. J Med Microbiol 2005; 54 (Pt 10) 975-979
• 99 Davis KK, Kao PN, Jacobs SS, Ruoss SJ. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med 2007; 7: 2
• 100 Colin AA. Eradication of mycobacterium abscessus in a chronically infected patient with cystic fibrosis. Pediatr Pulmonol 2000; 30 (3) 267-268
• 101 Colin AA, Ali-Dinar T. Aerosolized amikacin and oral clarithromycin to eradicate Mycobacterium abscessus in a patient with cystic fibrosis: an 8-year follow-up. Pediatr Pulmonol 2010; 45 (6) 626-627
• 102 Chbeir E, Casas L, Toubia N, Tawk M, Brown B. Adult cystic fibrosis presenting with recurrent non-tuberculous mycobacterial infections. Lancet 2006; 367 (9526) 1952
• 103 Oermann CM, Starke JR, Seilheimer DK. Pulmonary disease caused by Mycobacterium kansasii in a patient with cystic fibrosis. Pediatr Infect Dis J 1997; 16 (2) 257-259
• 104 Kinney JS, Little BJ, Yolken RH, Rosenstein BJ. Mycobacterium avium complex in a patient with cystic fibrosis: disease vs. colonization. Pediatr Infect Dis J 1989; 8 (6) 393-396
• 105 Koh WJ, Kim YH, Kwon OJ , et al. Surgical treatment of pulmonary diseases due to nontuberculous mycobacteria. J Korean Med Sci 2008; 23 (3) 397-401
• 106 Nelson KG, Griffith DE, Brown BA, Wallace Jr RJ. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann Thorac Surg 1998; 66 (2) 325-330
• 107 Yu JA, Pomerantz M, Bishop A, Weyant MJ, Mitchell JD. Lady Windermere revisited: treatment with thoracoscopic lobectomy/segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease. Eur J Cardiothorac Surg 2011; 40 (3) 671-675
• 108 Mitchell JD, Bishop A, Cafaro A, Weyant MJ, Pomerantz M. Anatomic lung resection for nontuberculous mycobacterial disease. Ann Thorac Surg 2008; 85 (6) 1887-1892 , discussion 1892–1893
• 109 Lucas J, Connett GJ, Lea R, Rolles CJ, Warner JO. Lung resection in cystic fibrosis patients with localised pulmonary disease. Arch Dis Child 1996; 74 (5) 449-451
• 110 Steinkamp G, von der Hardt H, Zimmermann HJ. Pulmonary resection for localized bronchiectasis in cystic fibrosis. Report of three cases and review of the literature. Acta Paediatr Scand 1988; 77 (4) 569-575
• 111 Marmon L, Schidlow D, Palmer J, Balsara RK, Dunn JM. Pulmonary resection for complications of cystic fibrosis. J Pediatr Surg 1983; 18 (6) 811-815
• 112 Camargos P, Le Bourgeois M, Revillon Y , et al. Lung resection in cystic fibrosis: a survival analysis. Pediatr Pulmonol 2008; 43 (1) 72-76
• 113 Levitsky S, Lapey A, Di Sant-Agnese PA. Pulmonary resection for life-threatening hemoptysis in cystic fibrosis. JAMA 1970; 213 (1) 125-127
• 114 Smith MB, Hardin Jr WD, Dressel DA, Beckerman RC, Moynihan PC. Predicting outcome following pulmonary resection in cystic fibrosis patients. J Pediatr Surg 1991; 26 (6) 655-659
• 115 Weiss ES, Allen JG, Merlo CA, Conte JV, Shah AS. Factors indicative of long-term survival after lung transplantation: a review of 836 10-year survivors. J Heart Lung Transplant 2010; 29 (3) 240-246
• 116 Christie JD, Edwards LB, Kucheryavaya AY , et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report—2010. J Heart Lung Transplant 2010; 29 (10) 1104-1118
• 117 Chalermskulrat W, Sood N, Neuringer IP , et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61 (6) 507-513
• 118 Kesten S, Chaparro C. Mycobacterial infections in lung transplant recipients. Chest 1999; 115 (3) 741-745
• 119 Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999; 160 (5 Pt 1) 1611-1616
• 120 Bonvillain RW, Valentine VG, Lombard G, LaPlace S, Dhillon G, Wang G. Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation. J Heart Lung Transplant 2007; 26 (9) 890-897
• 121 Knoll BM, Kappagoda S, Gill RR et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis 2012; 14 (5) 452-460
• 122 Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med 1994; 149 (6) 1601-1607
• 123 Sanguinetti M, Ardito F, Fiscarelli E , et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001; 39 (2) 816-819
• 124 Taylor JL, Palmer SM. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant 2006; 25 (8) 985-988
• 125 Gilljam M, Scherstén H, Silverborn M, Jönsson B, Ericsson Hollsing A. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J Cyst Fibros 2010; 9 (4) 272-276
• 126 Zaidi S, Elidemir O, Heinle JS , et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009; 11 (3) 243-248
• 127 Morales P, Gil A, Santos M. Mycobacterium abscessus infection in transplant recipients. Transplant Proc 2010; 42 (8) 3058-3060
• 128 Watkins RR, Lemonovich TL. Evaluation of infections in the lung transplant patient. Curr Opin Infect Dis 2012; 25 (2) 193-198
• 129 Luong ML, Morrissey O, Husain S. Assessment of infection risks prior to lung transplantation. Curr Opin Infect Dis 2010; 23 (6) 578-583
• 130 Chernenko SM, Humar A, Hutcheon M , et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006; 25 (12) 1447-1455